These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL). Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274 [TBL] [Abstract][Full Text] [Related]
6. [Therapeutic management of central nervous system lymphomas in a single hematological institute]. Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. Cuneo A; Mato AR; Rigolin GM; Piciocchi A; Gentile M; Laurenti L; Allan JN; Pagel JM; Brander DM; Hill BT; Winter A; Lamanna N; Tam CS; Jacobs R; Lansigan F; Barr PM; Shadman M; Skarbnik AP; Pu JJ; Sehgal AR; Schuster SJ; Shah NN; Ujjani CS; Roeker L; Orlandi EM; Billio A; Trentin L; Spacek M; Marchetti M; Tedeschi A; Ilariucci F; Gaidano G; Doubek M; Farina L; Molica S; Di Raimondo F; Coscia M; Mauro FR; de la Serna J; Medina Perez A; Ferrarini I; Cimino G; Cavallari M; Cucci R; Vignetti M; Foà R; Ghia P; Cancer Med; 2020 Nov; 9(22):8468-8479. PubMed ID: 32969597 [TBL] [Abstract][Full Text] [Related]
8. Comparing the Efficacy of DeVIC Therapy and High-dose Methotrexate Monotherapy with Whole-brain Radiation Therapy for Newly-diagnosed Primary Central Nervous System Lymphoma: A Single Institution Study. Chalise L; Motomura K; Ohka F; Hirano M; Hara M; Nishimura Y; Natsume A; Wakabayashi T Anticancer Res; 2017 Sep; 37(9):5215-5223. PubMed ID: 28870957 [TBL] [Abstract][Full Text] [Related]
9. Ibrutinib in primary central nervous system diffuse large B-cell lymphoma. T Low J; B Peters K CNS Oncol; 2020 Mar; 9(1):CNS51. PubMed ID: 32141313 [TBL] [Abstract][Full Text] [Related]
10. Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience. Lewis KL; Chin CK; Manos K; Casey J; Hamad N; Crawford J; Ho SJ; Issa S; Grigg A; Wood P; Gandhi MK; Do B; Nastoupil L; Hawkes EA; Cheah CY Br J Haematol; 2021 Mar; 192(6):1049-1053. PubMed ID: 32677095 [TBL] [Abstract][Full Text] [Related]
11. Ibrutinib combinations in CLL therapy: scientific rationale and clinical results. Timofeeva N; Gandhi V Blood Cancer J; 2021 Apr; 11(4):79. PubMed ID: 33927183 [TBL] [Abstract][Full Text] [Related]
12. A prospective cohort study of methotrexate plus idarubicin in newly diagnosed primary CNS lymphoma. Li Q; Ma Y; Lin Z; Ma J; Kang H; Zhang M; Xu H; Chen B J Neurooncol; 2023 May; 163(1):39-46. PubMed ID: 35733032 [TBL] [Abstract][Full Text] [Related]
13. A phase 2 study of ibrutinib maintenance following first-line high-dose methotrexate-based chemotherapy for elderly patients with primary central nervous system lymphoma. Bairey O; Taliansky A; Glik A; Amiel A; Yust-Katz S; Gurion R; Zektser M; Porges T; Sarid N; Horowitz NA; Shina TT; Lebel E; Cohen A; Geiger KR; Raanani P; Wolach O; Siegal T Cancer; 2023 Dec; 129(24):3905-3914. PubMed ID: 37572086 [TBL] [Abstract][Full Text] [Related]
14. Outcome of patients with newly diagnosed primary CNS lymphoma after high-dose methotrexate followed by consolidation whole-brain radiotherapy and cytarabine: an 8-year cohort study. Piriyakhuntorn P; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Rattarittamrong E; Tantiworawit A; Norasetthada L Int J Clin Oncol; 2021 Oct; 26(10):1805-1811. PubMed ID: 34236556 [TBL] [Abstract][Full Text] [Related]
15. High-dose methotrexate-based regimens and post-remission consolidation for treatment of newly diagnosed primary CNS lymphoma: meta-analysis of clinical trials. Yu J; Du H; Ye X; Zhang L; Xiao H Sci Rep; 2021 Jan; 11(1):2125. PubMed ID: 33483528 [TBL] [Abstract][Full Text] [Related]
16. High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma. Holdhoff M; Ambady P; Abdelaziz A; Sarai G; Bonekamp D; Blakeley J; Grossman SA; Ye X Neurology; 2014 Jul; 83(3):235-9. PubMed ID: 24928128 [TBL] [Abstract][Full Text] [Related]
17. The role of upfront lenalidomide maintenance for primary central nervous system lymphoma following first-line methotrexate treatment: A retrospective study. Zhang Y; Wang W; Zhao D; Chong W; Chen C; Zhang W; Zhou D Cancer Med; 2024 May; 13(9):e7193. PubMed ID: 38738459 [TBL] [Abstract][Full Text] [Related]
18. Impact of contemporary regimens on the outcomes and toxicity of primary CNS lymphoma: a single-center retrospective analysis of 73 patients. Sarid N; Bokstein F; Blumenthal DT; Weiss-Meilik A; Gibstein L; Avivi I; Perry C; Ram R J Neurooncol; 2021 Jan; 151(2):211-220. PubMed ID: 33099747 [TBL] [Abstract][Full Text] [Related]
19. High-dose methotrexate and rituximab induction regimen in immunocompetent patients with primary CNS lymphoma: a retrospective single-center study of survival predictors. DeAtkine AB; Abdelrashid M; Tucker Z; Mehta A; Markert JM; Kim J; Fiveash JB; Oster RA; Lobbous M; Nabors LB J Neurooncol; 2022 May; 158(1):33-40. PubMed ID: 35441948 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of HD-MTX based systemic chemotherapy regimens: retrospective study of induction therapy for primary central nervous system lymphoma in Chinese. Han X; Ji Y; Ouyang M; Zhu T; Zhou D Sci Rep; 2017 Dec; 7(1):17053. PubMed ID: 29213063 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]